EGFR and non-small cell lung carcinoma: EGFR is directly targeted by miR-128b and miR-128b loss-of-heterozygosity (LOH), which is frequently found in NSCLC, is a direct regulator of EGFR, correlates with clinical response and survival following gefitinib therapy (Weiss et al., 2008).